Caisse DE Depot ET Placement DU Quebec Makes New Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

Caisse DE Depot ET Placement DU Quebec purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 69,864 shares of the company's stock, valued at approximately $23,321,000. Caisse DE Depot ET Placement DU Quebec owned 0.22% of Medpace as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Tidal Investments LLC increased its stake in shares of Medpace by 16.2% in the first quarter. Tidal Investments LLC now owns 874 shares of the company's stock worth $353,000 after purchasing an additional 122 shares in the last quarter. Cetera Investment Advisers grew its stake in Medpace by 235.0% in the 1st quarter. Cetera Investment Advisers now owns 11,494 shares of the company's stock valued at $4,645,000 after buying an additional 8,063 shares in the last quarter. Cetera Advisors LLC raised its holdings in Medpace by 162.4% during the 1st quarter. Cetera Advisors LLC now owns 2,608 shares of the company's stock valued at $1,054,000 after acquiring an additional 1,614 shares during the period. GAMMA Investing LLC lifted its position in shares of Medpace by 58.4% during the second quarter. GAMMA Investing LLC now owns 236 shares of the company's stock worth $97,000 after acquiring an additional 87 shares in the last quarter. Finally, CWM LLC boosted its holdings in shares of Medpace by 38.8% in the second quarter. CWM LLC now owns 2,323 shares of the company's stock worth $957,000 after acquiring an additional 649 shares during the period. Hedge funds and other institutional investors own 77.98% of the company's stock.

Medpace Trading Up 0.5 %

Shares of Medpace stock traded up $1.73 on Monday, hitting $342.36. 193,034 shares of the company traded hands, compared to its average volume of 284,021. Medpace Holdings, Inc. has a 12-month low of $273.14 and a 12-month high of $459.77. The company has a market cap of $10.64 billion, a P/E ratio of 29.98, a P/E/G ratio of 1.88 and a beta of 1.37. The firm's 50-day simple moving average is $337.43 and its 200 day simple moving average is $370.62.

Medpace (NASDAQ:MEDP - Get Free Report) last released its quarterly earnings results on Monday, October 21st. The company reported $3.01 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.24. The business had revenue of $533.32 million for the quarter, compared to the consensus estimate of $540.99 million. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The company's revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter last year, the business posted $2.22 earnings per share. Analysts predict that Medpace Holdings, Inc. will post 11.93 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. TD Cowen dropped their price objective on Medpace from $413.00 to $372.00 and set a "buy" rating on the stock in a report on Wednesday, October 23rd. Robert W. Baird increased their price target on shares of Medpace from $349.00 to $354.00 and gave the stock a "neutral" rating in a report on Monday, November 25th. Truist Financial reduced their price objective on shares of Medpace from $415.00 to $397.00 and set a "hold" rating for the company in a research note on Monday, October 14th. Redburn Atlantic assumed coverage on shares of Medpace in a report on Monday, October 14th. They set a "buy" rating and a $404.00 target price on the stock. Finally, StockNews.com downgraded shares of Medpace from a "buy" rating to a "hold" rating in a report on Friday, September 27th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $380.56.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.